KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program
October 10, 2014 19:48 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Oct. 10, 2014 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that on September 26, 2014, the Compensation Committee of the Company's Board...
KYTHERA Biopharmaceuticals Submits New Drug Submission to Health Canada for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat
August 11, 2014 16:05 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it submitted a New Drug Submission (NDS) to Health Canada seeking approval...
KYTHERA Biopharmaceuticals Releases Second Quarter 2014 Operating Results
August 07, 2014 16:05 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Aug. 7, 2014 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc.(Nasdaq:KYTH) today reported financial results for its second quarter 2014 and provided an update on recent...
KYTHERA Biopharmaceuticals to Release Second Quarter 2014 Operating Results
July 31, 2014 16:17 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., July 31, 2014 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it will release its second quarter 2014 operating results and will host an...
KYTHERA Biopharmaceuticals Announces FDA Acceptance of ATX-101 New Drug Application
July 10, 2014 16:32 ET
|
KYTHERA Biopharmaceuticals, Inc.
CALABASAS, Calif., July 10, 2014 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that its New Drug Application (NDA) for ATX-101 (deoxycholic acid), has been...
KYTHERA Biopharmaceuticals to Present at the Goldman Sachs 35th Annual Global Healthcare Conference
June 06, 2014 17:21 ET
|
KYTHERA Biopharmaceuticals, Inc.
CALABASAS, Calif., June 6, 2014 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the...
KYTHERA Biopharmaceuticals Submits New Drug Application for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat
May 12, 2014 19:30 ET
|
KYTHERA Biopharmaceuticals, Inc.
CALABASAS, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug...
KYTHERA Biopharmaceuticals Releases First Quarter 2014 Operating Results
May 08, 2014 16:05 ET
|
KYTHERA Biopharmaceuticals, Inc.
CALABASAS, Calif., May 8, 2014 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today reported financial results for its first quarter 2014, and provided an update on recent...
KYTHERA Biopharmaceuticals to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
May 07, 2014 16:05 ET
|
KYTHERA Biopharmaceuticals, Inc.
CALABASAS, Calif., May 7, 2014 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the Bank of...
KYTHERA Biopharmaceuticals to Release First Quarter 2014 Operating Results
April 24, 2014 17:05 ET
|
KYTHERA Biopharmaceuticals, Inc.
CALABASAS, Calif., April 24, 2014 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it will release its first quarter 2014 operating results and will host an investor...